Lixisenatide/insulin glargine

Drug Profile

Lixisenatide/insulin glargine

Alternative Names: AVE0010/Lantus®; HOE901/AVE0010; iGlarLixi; Insulin glargine/lixisenatide; Lantus®/lixisenatide single combination product; Lantus®/Lyxumia®; LixiLan; Lixisenatide + Lantus®; Lixisenatide/Lantus®; Lyxumia®/Lantus®; Soliqua; Soliqua®100/33; Suliqua

Latest Information Update: 16 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi-aventis; Zealand Pharma
  • Developer Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 10 Jun 2017 Updated Efficacy data from the post-hoc analysis of the LixiLan-L phase III trial in Type-2 diabetes mellitus released by Zealand
  • 17 May 2017 Launched for Type-2 diabetes mellitus (New delivery system) in Netherlands (SC)
  • 18 Jan 2017 Registered for Type-2 diabetes mellitus (New delivery system) in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top